New combo therapy aims to supercharge immune cells against tough melanoma
NCT ID NCT06940739
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug (IOV-3001) designed to boost immune cells in people with advanced melanoma that has not responded to prior treatments. About 42 adults will receive the drug alongside a personalized cell therapy called lifileucel. The main goals are to check safety and find the best dose, while also measuring how the drug behaves in the body and affects the immune system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Greenslopes Private Hospital
RECRUITINGGreenslopes, Queensland, 4120, Australia
-
Hollywood Private Hospital Ramsay
RECRUITINGNedlands, Western Australia, 6009, Australia
-
SCRI Oncology Partners- Denver
RECRUITINGDenver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
UNC Hospitals, The University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27514, United States